Characteristic |
Overall, N = 62 |
Post-ICI, N = 52 |
Pre-ICI, N = 10 |
p-value |
|---|---|---|---|---|
| Age, years | 69 (60, 76) | 70 (63, 76) | 52 (42, 68) | 0.009 |
| Male gender | 30 (48%) | 27 (52%) | 3 (30%) | 0.3 |
| Race | 0.052 | |||
| Asian | 1 (1.6%) | 0 (0%) | 1 (10%) | |
| Black | 13 (21%) | 9 (17%) | 4 (40%) | |
| Unknown | 1 (1.6%) | 1 (1.9%) | 0 (0%) | |
| White | 47 (76%) | 42 (81%) | 5 (50%) | |
| Hispanic Ethnicity | 3 (4.8%) | 2 (3.8%) | 1 (10%) | 0.4 |
| Prior MI | 12 (19%) | 12 (23%) | 0 (0%) | 0.2 |
| Any Coronary Artery Disease | 36 (58%) | 34 (65%) | 2 (20%) | 0.013 |
| Cerebrovascular Accident | 2 (3.2%) | 2 (3.8%) | 0 (0%) | >0.9 |
| Diabetes Mellitus | 16 (26%) | 14 (27%) | 2 (20%) | >0.9 |
| Hypertension | 46 (74%) | 40 (77%) | 6 (60%) | 0.3 |
| Hyperlipidemia | 40 (65%) | 37 (71%) | 3 (30%) | 0.026 |
| Active smoking | 6 (9.7%) | 6 (12%) | 0 (0%) | 0.6 |
| Arrhythmia | 17 (27%) | 16 (31%) | 1 (10%) | 0.3 |
| Systolic Dysfunction | 15 (24%) | 14 (27%) | 1 (10%) | 0.4 |
| Diastolic Dysfunction | 6 (9.7%) | 5 (9.6%) | 1 (10%) | >0.9 |
| Chronic Kidney Disease | 7 (11%) | 6 (12%) | 1 (10%) | >0.9 |
| Cancer Type | 0.009 | |||
| Brain | 1 (1.6%) | 1 (1.9%) | 0 (0%) | |
| Breast | 12 (19%) | 5 (9.6%) | 7 (70%) | |
| Gastrointestinal | 1 (1.6%) | 1 (1.9%) | 0 (0%) | |
| Genitourinary | 12 (19%) | 12 (23%) | 0 (0%) | |
| Liver | 2 (3.2%) | 2 (3.8%) | 0 (0%) | |
| Lung | 17 (27%) | 14 (27%) | 3 (30%) | |
| Mesothelioma | 1 (1.6%) | 1 (1.9%) | 0 (0%) | |
| Pancreatic | 2 (3.2%) | 2 (3.8%) | 0 (0%) | |
| Skin | 13 (21%) | 13 (25%) | 0 (0%) | |
| Unknown | 1 (1.6%) | 1 (1.9%) | 0 (0%) | |
| Metastatic Cancer | 46 (74%) | 44 (85%) | 2 (20%) | <0.001 |
Initial Tables ICI myocarditis project
Demographics
Cardiovascular therapy
Characteristic |
Overall, N = 62 |
Post-ICI, N = 52 |
Pre-ICI, N = 10 |
p-value |
|---|---|---|---|---|
| Beta Blocker | 23 (38%) | 22 (43%) | 1 (10%) | 0.074 |
| ACE Inhibitor or ARB | 22 (35%) | 20 (38%) | 2 (20%) | 0.5 |
| Aldactone | 2 (3.2%) | 2 (3.8%) | 0 (0%) | >0.9 |
| Statin | 34 (55%) | 32 (62%) | 2 (20%) | 0.033 |
| DOAC or Coumadin | 14 (23%) | 14 (27%) | 0 (0%) | 0.10 |
| Aspirin | 22 (35%) | 20 (38%) | 2 (20%) | 0.5 |
| Sacubitril / Valsartan | 3 (4.8%) | 2 (3.8%) | 1 (10%) | 0.4 |
| SGLT2 Inhibitor | 1 (1.6%) | 1 (1.9%) | 0 (0%) | >0.9 |
I removed PCSK9 from the above table because nobody was reported as being on it.
Oncologic therapy
Characteristic |
Overall, N = 62 |
Post-ICI, N = 52 |
Pre-ICI, N = 10 |
p-value |
|---|---|---|---|---|
| Anthracycline | 9 (15%) | 6 (12%) | 3 (30%) | 0.2 |
| Monoclonal Antibody | 18 (39%) | 12 (33%) | 6 (60%) | 0.2 |
| Alkylating Agent | 11 (18%) | 6 (12%) | 5 (50%) | 0.011 |
| Protein Kinase Inhibitor | 12 (19%) | 12 (23%) | 0 (0%) | 0.2 |
| Taxol | 29 (47%) | 20 (38%) | 9 (90%) | 0.004 |
| 5-Fluorouracil | 5 (8.3%) | 5 (10%) | 0 (0%) | 0.6 |
| Carboplatin | 31 (51%) | 24 (47%) | 7 (70%) | 0.3 |
ICI therapy
Characteristic |
Overall, N = 62 |
Post-ICI, N = 52 |
Pre-ICI, N = 10 |
p-value |
|---|---|---|---|---|
| Checkpoint Inhibitor | 60 (97%) | 51 (98%) | 9 (90%) | 0.3 |
| Atezolizumab | 6 (9.7%) | 6 (12%) | 0 (0%) | 0.6 |
| Pembrolizumab | 32 (52%) | 26 (50%) | 6 (60%) | 0.7 |
| Ipilimumab | 13 (21%) | 12 (23%) | 1 (10%) | 0.7 |
| Nivolumab | 16 (26%) | 15 (29%) | 1 (10%) | 0.4 |
| Durvalumab | 9 (15%) | 7 (13%) | 2 (20%) | 0.6 |
| Tremelimumab | 1 (1.6%) | 1 (1.9%) | 0 (0%) | >0.9 |
| Dual Immune Checkpoint Inhibitor | 12 (19%) | 11 (21%) | 1 (10%) | 0.7 |
ICI is not 100%, but should be, we can just remove this variable from the table instead of fixing it, should not be a problem.
Myocarditis and treatment
Characteristic |
Overall, N = 62 |
Post-ICI, N = 52 |
Pre-ICI, N = 10 |
p-value |
|---|---|---|---|---|
| Clinicl Myocarditis Diagnosis | 33 (53%) | 33 (63%) | 0 (0%) | <0.001 |
| Myocarditis Treated | 35 (60%) | 35 (73%) | 0 (0%) | <0.001 |
| Pulse Dose Steroid | 36 (58%) | 36 (69%) | 0 (0%) | <0.001 |
| Cellcept | 15 (24%) | 15 (29%) | 0 (0%) | 0.10 |
| Abatacept | 6 (9.7%) | 6 (12%) | 0 (0%) | 0.6 |
| Infliximab | 1 (1.6%) | 1 (1.9%) | 0 (0%) | >0.9 |
| IVIG | 6 (9.7%) | 6 (12%) | 0 (0%) | 0.6 |
| Tofacitinib | 2 (3.2%) | 2 (3.8%) | 0 (0%) | >0.9 |
Cardiovascular outcomes
Characteristic |
Overall, N = 62 |
Post-ICI, N = 52 |
Pre-ICI, N = 10 |
p-value |
|---|---|---|---|---|
| ACE including death | 45 (73%) | 43 (83%) | 2 (20%) | <0.001 |
| ACE excluding death | 35 (56%) | 33 (63%) | 2 (20%) | 0.016 |
| Myocardial Infarction | 3 (4.8%) | 3 (5.8%) | 0 (0%) | >0.9 |
| Arhythmia | 10 (16%) | 10 (19%) | 0 (0%) | 0.2 |
| Cardiomyopathy | 25 (40%) | 23 (44%) | 2 (20%) | 0.2 |
| Heart Failure | 15 (24%) | 15 (29%) | 0 (0%) | 0.10 |
| Death | 26 (42%) | 26 (50%) | 0 (0%) | 0.003 |
Outcomes only in ICI myocarditis arm by treatment
Characteristic |
Overall, N = 48 |
Myocarditis treated, N = 35 |
No treatment, N = 13 |
p-value |
|---|---|---|---|---|
| ACE including death | 39 (81%) | 31 (89%) | 8 (62%) | 0.048 |
| ACE excluding death | 31 (65%) | 25 (71%) | 6 (46%) | 0.2 |
| Myocardial Infarction | 3 (6.3%) | 2 (5.7%) | 1 (7.7%) | >0.9 |
| Arhythmia | 10 (21%) | 6 (17%) | 4 (31%) | 0.4 |
| Cardiomyopathy | 22 (46%) | 21 (60%) | 1 (7.7%) | 0.001 |
| Heart Failure | 14 (29%) | 13 (37%) | 1 (7.7%) | 0.073 |
| Death | 23 (48%) | 20 (57%) | 3 (23%) | 0.036 |